KYMR

Kymera Therapeutics Inc. (KYMR) | Rumor.io

Kymera Therapeutics

KYMR

Attention (50-day avg)0%

Attention rank (50-day avg)#1,083

Bullish sentiment (50-day avg)100%

Price to earnings ratio-30.4

Market capitalization9.3B

Earnings per share-3.25

Dividend yield (TTM)—

Revenue (annual)39.2M

Net income (annual)-311.4M

Social

What share of all stock conversation is about KYMR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 27

Insider selling activity has been observed with 627,597 shares of $KYMR sold by BVF Partners L P/IL at $106.50.
The total value of the sale was $66.8M.
This move can be tracked by following insider activity on the platform.

Generated by AI

Sentiment

Of the messages about KYMR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	74.57% -22.57
Bearish	—	—	0% 0	25.43% +22.57

Bullish· Dec 9

Kymera Therapeutics' market value increased by $3.5B following Phase 1B trial data, with analysts expecting FDA approval.
Multiple brokerages have raised their price targets for the company, with some setting targets as high as $138, indicating strong bullish sentiment.
The stock has seen significant trading activity, with one trader reporting a 34% ROI on a call option trade, and institutional ownership may help prop up the stock.

Bearish· Dec 8

The author believes $KYMR is over-valued, citing a $7.27B market capitalization, a history of discontinued drugs, and lack of Phase 2b data until Q3 2027.
The company's recent public offering of $575 million via dilution is seen as a bearish sign, with prices potentially dropping to around $80.
Insiders are allegedly dumping shares, and the author is skeptical of the study's early results, suggesting that the stock may be a "bull trap" or subject to manipulation.

Generated by AI

Topics

Of the messages about KYMR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	76.6%	77.47%
Technical Analysis	—	—	1.06%	4.28%
Analysts	—	—	22.34%	11.18%
Earnings	—	—	0%	0.3%
Controversies	—	—	0%	0.03%
Macro	—	—	0%	6.74%

Analysts· Dec 9

Analysts at Oppenheimer raised their price target for Kymera Therapeutics (KYMR) to $120 from $67.
Multiple analysts, including Morgan Stanley, BTIG, and BofA Securities, have raised their price targets for KYMR, with targets ranging from $112 to $138.
Analysts at Piper Sandler, Wells Fargo, and Barclays have also raised their price targets for KYMR, with targets at $125, $116, and $119, respectively.

Announcements· Dec 11

Kymera Therapeutics, Inc. ($KYMR) has been granted FDA Fast Track Designation for KT-621, a first-in-class oral STAT6 degrader for the treatment of atopic dermatitis.
The company has announced the closing of an upsized $602 million public offering and the full exercise of underwriters' option to purchase additional shares.
Insider BAKER BROS. ADVISORS LP has purchased 2,005,813 shares of $KYMR worth $172,499,918.00, indicating a significant buy signal.

Generated by AI

Community

Of the messages about KYMR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	81.1%	80.41%
Newcomers	—	—	18.9%	19.59%

Regulars· Dec 9

$KYMR's market capitalization is approximately $7B, compared to $CRVS's $630M.
Regulars highlight the differences in trial designs between $KYMR's Phase 1b EASI results and $CRVS's ITK inhibitor #soquelitinib data.
Analysts have upgraded $KYMR's price target, with firms such as Jefferies, Morgan Stanley, and Oppenheimer raising their estimates by $49-$67 per share.

Newcomers· Jun 27

A large insider sell was reported for $KYMR, with 627,597 shares sold at $106.50 by BVF Partners L P/IL.
The sale represents a significant amount of $66.8M, which may indicate a decrease in the seller's confidence in the company's future prospects.
This insider sell may be a concern for investors, as it could suggest that the seller believes the stock price will decline.

Generated by AI

News

Also Discussed

Investors talking about KYMR also mention

#	Name	Attention
1	Nurix Therapeutics, Inc.NRIX	0%new
2	Relay Therapeutics Inc.RLAY	0%new
3	Cullinan Therapeutics Inc.CGEM	0%new
4	Kulicke & Soffa Industries, Inc.KLIC	0%0
5	Arcus Biosciences, Inc.RCUS	0%new
6	Cohu, Inc.COHU	0.01%-0.03
7	Xometry Inc.XMTR	0%new
8	Extreme Networks Inc.EXTR	0%new
9	Tango Therapeutics Inc.TNGX	0%new
10	Ultra Clean Holdings, Inc.UCTT	0%0

Kymera Therapeutics Inc.

Healthcare
Biotechnology

Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins. The company’s work centers on harnessing the body’s natural protein recycling systems to create oral therapies designed for conditions that are difficult to treat with conventional approaches. Its current programs span immunology, inflammation, and oncology, with research aimed at diseases such as atopic dermatitis, hidradenitis suppurativa, autoimmune disorders, and certain cancers. Kymera Therapeutics Inc. operates through a differentiated drug-discovery platform that supports both internal pipeline development and strategic research collaborations. Headquartered in Watertown, Massachusetts, the company plays a specialized role in the biotechnology market by advancing novel treatment approaches for serious diseases.

Website

Location

500 North Beacon Street

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about KYMR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 27

Insider selling activity has been observed with 627,597 shares of $KYMR sold by BVF Partners L P/IL at $106.50.
The total value of the sale was $66.8M.
This move can be tracked by following insider activity on the platform.

Generated by AI

Sentiment

Of the messages about KYMR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	74.57% -22.57
Bearish	—	—	0% 0	25.43% +22.57

Bullish· Dec 9

Kymera Therapeutics' market value increased by $3.5B following Phase 1B trial data, with analysts expecting FDA approval.
Multiple brokerages have raised their price targets for the company, with some setting targets as high as $138, indicating strong bullish sentiment.
The stock has seen significant trading activity, with one trader reporting a 34% ROI on a call option trade, and institutional ownership may help prop up the stock.

Bearish· Dec 8

The author believes $KYMR is over-valued, citing a $7.27B market capitalization, a history of discontinued drugs, and lack of Phase 2b data until Q3 2027.
The company's recent public offering of $575 million via dilution is seen as a bearish sign, with prices potentially dropping to around $80.
Insiders are allegedly dumping shares, and the author is skeptical of the study's early results, suggesting that the stock may be a "bull trap" or subject to manipulation.

Generated by AI

Topics

Of the messages about KYMR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	76.6%	77.47%
Technical Analysis	—	—	1.06%	4.28%
Analysts	—	—	22.34%	11.18%
Earnings	—	—	0%	0.3%
Controversies	—	—	0%	0.03%
Macro	—	—	0%	6.74%

Analysts· Dec 9

Analysts at Oppenheimer raised their price target for Kymera Therapeutics (KYMR) to $120 from $67.
Multiple analysts, including Morgan Stanley, BTIG, and BofA Securities, have raised their price targets for KYMR, with targets ranging from $112 to $138.
Analysts at Piper Sandler, Wells Fargo, and Barclays have also raised their price targets for KYMR, with targets at $125, $116, and $119, respectively.

Announcements· Dec 11

Kymera Therapeutics, Inc. ($KYMR) has been granted FDA Fast Track Designation for KT-621, a first-in-class oral STAT6 degrader for the treatment of atopic dermatitis.
The company has announced the closing of an upsized $602 million public offering and the full exercise of underwriters' option to purchase additional shares.
Insider BAKER BROS. ADVISORS LP has purchased 2,005,813 shares of $KYMR worth $172,499,918.00, indicating a significant buy signal.

Generated by AI

Community

Of the messages about KYMR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	81.1%	80.41%
Newcomers	—	—	18.9%	19.59%

Regulars· Dec 9

$KYMR's market capitalization is approximately $7B, compared to $CRVS's $630M.
Regulars highlight the differences in trial designs between $KYMR's Phase 1b EASI results and $CRVS's ITK inhibitor #soquelitinib data.
Analysts have upgraded $KYMR's price target, with firms such as Jefferies, Morgan Stanley, and Oppenheimer raising their estimates by $49-$67 per share.

Newcomers· Jun 27

A large insider sell was reported for $KYMR, with 627,597 shares sold at $106.50 by BVF Partners L P/IL.
The sale represents a significant amount of $66.8M, which may indicate a decrease in the seller's confidence in the company's future prospects.
This insider sell may be a concern for investors, as it could suggest that the seller believes the stock price will decline.

Generated by AI

Kymera Therapeutics

Social

Jun 27

Bullish· Dec 9

Bearish· Dec 8

Analysts· Dec 9

Announcements· Dec 11

Regulars· Dec 9

Newcomers· Jun 27

Kymera Therapeutics at Stifel forum: faster path for lead drug

Goldman Sachs resumes Kymera Therapeutics stock coverage

Piper Sandler reiterates Kymera Therapeutics stock rating at $140

Stifel raises Kymera Therapeutics price target on drug trial outlook

Kymera Therapeutics at Morgan Stanley conference: oral degrader push

Kymera Therapeutics at H.C. Wainwright: oral drug push gains pace

Also Discussed

Kymera Therapeutics Inc.

Company Information

Location

Kymera Therapeutics at Stifel forum: faster path for lead drug

Goldman Sachs resumes Kymera Therapeutics stock coverage

Piper Sandler reiterates Kymera Therapeutics stock rating at $140

Stifel raises Kymera Therapeutics price target on drug trial outlook

Kymera Therapeutics at Morgan Stanley conference: oral degrader push

Kymera Therapeutics at H.C. Wainwright: oral drug push gains pace

Also Discussed

Social

Jun 27

Bullish· Dec 9

Bearish· Dec 8

Analysts· Dec 9

Announcements· Dec 11

Regulars· Dec 9

Newcomers· Jun 27